NanoHybrid is a technology platform based on proprietary, ready-to-use nanoreagents enabling instantaneous detection protein biomarkers (such as antibodies) in complex matrices such as blood serum. Ulisse BioMed is developing the technology both in a lab format and in a point-of-care version. What makes our products unique is the flexibility of our technology, which enables us to bring the diagnostic answer exactly where and when is needed.
Biological drugs represented a breakthrough in the management of diseases affecting millions of people worldwide.
However, less than half patients do not respond to these drugs with several negative consequences. Relatively to the individual patient, heavy side effects become unjustifiable if no therapeutic benefits are achieved, whereas precious time is dangerously loss and ineffective drug administration postpones more adequate therapeutic intervention. At healthcare level, given their high cost, biological drugs should be better targeted to the patients which have the highest chance to benefit from their usage.
Biological drug monitoring (BDM) is the measurement of biologic drug levels in patients’ blood, and it is one of the main pillars of personalized medicine. Indeed, the information provided by BDM enables subsequent therapeutic decisions to better manage patient health, such as adjustment treatment intensity according to individual pharmacokinetics, or prompt drug change in case of ineffective treatment.
Besides evident advantages concerning the patients’ health and quality of life, BDM allows to better target each patient while minimizing off-target cost, decreasing the risk of later treatment failure linked to underexposure to the biological drug, and reducing treatment intensity to save costs in case of overexposure.
BDM is the measurement of the serum level of a biological drug, typically a monoclonal antibody (mAb) to ensure its concentration is within the therapeutic range. A drug's serum therapeutic range is the concentration range in which the drug is known to be effective while causing little or no toxic effects to the patient.
However traditional assays format, usually in precoated 96 wells plates, badly reconciles with the clinician’s need, that collect few samples per day and requires a rapid response in order to promptly intervene, and the laboratory’s need, that instead is forced to analyze samples periodically in grouped session. This format limits the diffusion of BDM in hospital and healthcare.
Ulisse BioMed aims to outrun traditional assays and to dictate new standard for BDM, through a pioneer approach based on NanoHybrid technology.
Ulisse BioMed is developing a full range of products to monitor patients prescribed with biologics or biosimilars, offering key information about drug availability and therapeutic efficacy.
